Mechanism of Action of Camptothecin
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gatto B. & L.F. Liu. 1998. Topoisomerase I‐targeting drugs: new developments in cancer pharmacology.InAdvances in DNA Sequence‐Specific Agents. M. Palumboet al. Eds. 8: 39–66. CRC Press Inc. Boca Raton FL.
Hsiang Y.H., 1988, Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin, Cancer Res., 48, 1722
Svejstrup J.Q., 1991, New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I, The mode of action of camptothecin at a specific recognition site. J Mol. Biol., 222, 669
Pilch D.S, 1996, Characterizing the DNA binding modes of a topoisomerase I‐ poisoning terbenzimidazole: evidence for both intercalative and minor groove binding properties, Drug Des. Discov., 13, 115
Poddevin B., 1993, Dual topoisomerase I and II inhibition by intoplicine (RP‐ 60475), a new antitumor agent in early clinical trials, Mol. Pharmacol., 44, 767
Yoshinari T., 1993, Induction of topoisomerase I‐mediated DNA cleavage by a new indolocarbazole, ED‐110, Cancer Res., 53, 490
Pourquier P., 1997, Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps, Importance of DNA end phosphorylation and camptothecin effects. J Biol. Chem., 272, 26441
D'Arpa P., 1990, Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons, Cancer Res., 50, 6919
Hsiang Y.H., 1989, Arrest of replication forks by drug‐stabilized topoisomerase I‐DNA cleavable complexes as a mechanism of cell killing by camptothecin, Cancer Res., 49, 5077
Tsao Y.P., 1992, The involvement of active DNA synthesis in camptothecin‐ induced G2 arrest: altered regulation of p34cdc2/cyclin B, Cancer Res., 52, 1823
Tsao Y.P., 1993, Interaction between replication forks and topoisomerase I‐ DNA cleavable complexes: studies in a cell‐free SV40 DNA replication system, Cancer Res., 53, 5908
Zhang H., 1990, A model for tumor cell killing by topoisomerase poisons, Cancer Cells, 2, 23
Huang T.T., 2000, NF‐kappaB activation by camptothecin, A linkage between nuclear DNA damage and cytoplasmic signaling events. J. Biol. Chem., 275, 9501
Goldwasser F., 1995, Topoisomerase I‐related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen, Cancer Res., 55, 2116
Hortwiz S.B., 1972, Studies on camptothecin I: effect on nucleic acid and protein synthesis, Mol. Pharmacol., 7, 632
Kann H.E., 1972, Effect of DNA‐reactive drugs on RNA synthesis patterns in L1210 cells, Mol. Pharmacol., 8, 551
Squires S., 1993, Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA, Cancer Res., 53, 2012
Beidler D.R., 1995, Camptothecin induction of a time‐ and concentration‐dependent decrease of topoisomerase I and its implication in camptothecin activity, Mol. Pharmacol., 47, 907
Boddy M.N., 1996, PIC 1, a novel ubiquitin‐like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia, Oncogene, 13, 971
Okura T., 1996, Protection against Fas/APO‐1 and tumor necrosis factor‐mediated cell death by a novel protein, sentrin, J. Immunol., 157, 4277, 10.4049/jimmunol.157.10.4277
Leroy L.F., 1999, The roles of ubiquitin‐dependent proteolysis in determining the sensitivity/resistance of tumor cells to topoisomerase inhibitors, Proc. Am. Assoc. Cancer Res, 40, 775
Gupta E., 1998, Clinical evaluation of sequential topoisomerase targeting in the treatment of advance maligancy, Cancer Ther., 1, 292